The article reviews studies highlighting multidisciplinary approaches and precision medicine in AD

Almost a quarter of all children and almost 10% of adults suffer from atopic dermatitis, a chronic and often permanent skin condition that can cause redness, itching and irritation.1 Although most common in childhood, this condition may disappear for a time and reappear in adulthood, going through periods of remission and flare-ups.

For a long time, atopic dermatitis has been associated with other conditions, but in recent years it has gained recognition for its own unique condition.

There are many triggers, causes, and manifestations of atopic dermatitis, and it can even show up later in life, sometimes even after age 60.

Managing atopic dermatitis can be challenging, especially since up to 20% of people with atopic dermatitis have a treatment-resistant form of the disease.1

A recent article reviewed a number of studies on treatment-resistant forms of atopic dermatitis and new strategies or therapies that may be useful in helping clinicians and their patients manage the disease.

The 2022 paper, Asia Pacific Allergy, reveals that the best approach to cases of atopic dermatitis that do not respond to traditional therapies often cannot be helped by a monotherapy approach. Multidisciplinary treatment that includes precision medicine and shared decision-making is essential, as patient engagement and compliance are important to the success of any treatment plan.1

These multi-factorial approaches can include things like oral, topical, and injectable medications, but teledermatology and other digital tools can help increase patient-clinician engagement, improve medication adherence, and identify patients more quickly. changes and triggers.

Amy Paller, MD, chair of the department of dermatology and director of the Skin Biology and Disease Resource-Based Center at Northwestern Medicine, says there is little new data presented in the article, but it highlights many key points. raised in several other research studies over the years. This includes a study co-authored by Paller in 2021 on a number of new targeted topical and systemic treatments for atopic dermatitis.2

While there are other studies that might be more effective in describing new therapies for the precision management of atopic dermatitis, Paller says the article is spot-on when it comes to telemedicine, which she says, ” can be useful for tracking patients who respond well, since we really can’t see skin lesions well directly in telemedicine and need good photographs.

As mentioned in the article, advances in telemedicine, particularly teledermatology, allow patients and clinicians to share information and images quickly and more easily, which helps improve follow-up care, patient engagement patients and adherence to treatment and care plans. Paller says there’s valuable information about a number of other new therapies in the article, including drugs like:1

  • Ruxolitinib
  • Tofacitinib
  • Delgocitinib
  • Abrocitinib
  • Baricitinib
  • Upadacitinib
  • Lebrikizumab
  • Nemolizumab
  • Omalizumab
  • Risankizumab
  • Tralokinumab
  • Ustekinumab

However, Paller says much more in-depth research on these treatments is available in dozens of other articles, especially in allergy-specific journals.

References:

1. Naik PP. Treatment-resistant atopic dermatitis: new therapies, digital tools and precision medicine. Asia-Pacific allergy. Apr 2022;12(2):e20. doi: 10.5415/apallergy.2022.12.e20.
https://apallergy.org/DOIx.php?id=10.5415/apallergy.2022.12.e20

2. Puar N, Chovatiya R, Paller AS. New treatments for atopic dermatitis. Annals of Allergy, Asthma and Immunology. 2021 Jan;126(1):21-31. doi:10.1016/j.anai.2020.08.016.
https://linkinghub.elsevier.com/retrieve/pii/S108112062030572X